Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

• David Muccino,
• George Philip,
• A.H. Morice,
• S.S. Birring,
• L. Mcgarvey,
• P.V. Dicpinigaitis,
• I.D. Pavord,
• A.M. Tershakovec,
• M.M. Kitt,
• C. Assaid,
• J.A. Smith

Affiliations

David Muccino

Merck & Co., Inc., Kenilworth, United States

George Philip

Merck & Co., Inc., Kenilworth, United States

A.H. Morice

Hull York Medical School, Cottingham, United Kingdom

S.S. Birring

King's College London, London, United Kingdom

L. Mcgarvey

Queen's University Belfast, Belfast, United Kingdom

P.V. Dicpinigaitis

Albert Einstein College of Medicine, Bronx, United States; Montefiore Medical Center, Bronx, United States

I.D. Pavord

University of Oxford, Oxford, United Kingdom

A.M. Tershakovec

Merck & Co., Inc., Kenilworth, United States

M.M. Kitt

Merck & Co., Inc., Kenilworth, United States

C. Assaid

Merck & Co., Inc., Kenilworth, United States

J.A. Smith

University of Manchester, Manchester, United Kingdom